Yu Chen
Research Subjects
Yu Chen has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
- David J. Rawlings
Center for Immunity and Immunotherapies, Seattle Children's Research Institute, Seattle, WA
3 shared publications - Christopher D. Thouvenel
Center for Immunity and Immunotherapies, Seattle Children’s Research Institute, Seattle, WA 1
2 shared publications - Jason Netland
Department of Immunology, University of Washington School of Medicine, Seattle, WA 2
2 shared publications - Marcos C. Miranda
Department of Biochemistry, University of Washington, Seattle, USA
2 shared publications - Marion Pepper
Department of Immunology, University of Washington, Seattle, USA
2 shared publications - Neil P. King
Institute for Protein Design, University of Washington, Seattle, WA, USA
2 shared publications
Latest Publications
- 22 October 2026
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 223 (11)
Antigen-independent BCR signals limit differentiation and survival of IgM antibody-secreting cells
IgM contributes to early and durable humoral immunity, yet the mechanisms governing human IgM plasma cell (PC) maturation and persistence remain unknown. Here, using an ex vivo human B cell system, we found that IgM B cell receptor (BCR) signaling restricts IgM antibody-secreting cell (ASC) differentiation and survival. Using CRISPR-mediated gene disruption and pharmacologic inhibition, we show that surface BCR and its proximal signaling components, particularly SYK, suppressed induction of IRF4 and PRDM1, thereby restraining PC differentiation. Concurrently, ligand-independent BCR signaling increased basal calcium flux and apoptosis in IgM plasmablasts. Inhibition of BCR-proximal signaling also increased PC numbers and persistence after in vivo engraftment. Leveraging this mechanistic insight, we demonstrated that SYK KO in engineered PCs (ePCs) significantly improved output and in vivo durability of IgM-cetuximab–secreting ePCs. Together, these findings reveal IgM-BCR signaling as a previously unrecognized negative regulator of human IgM PC differentiation and survival and show that inhibition of BCR-proximal pathways can improve IgM-based cellular immunotherapies.
- 22 October 2026
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 223 (11)
Antigen-independent BCR signals limit differentiation and survival of IgM antibody-secreting cells
IgM contributes to early and durable humoral immunity, yet the mechanisms governing human IgM plasma cell (PC) maturation and persistence remain unknown. Here, using an ex vivo human B cell system, we found that IgM B cell receptor (BCR) signaling restricts IgM antibody-secreting cell (ASC) differentiation and survival. Using CRISPR-mediated gene disruption and pharmacologic inhibition, we show that surface BCR and its proximal signaling components, particularly SYK, suppressed induction of IRF4 and PRDM1, thereby restraining PC differentiation. Concurrently, ligand-independent BCR signaling increased basal calcium flux and apoptosis in IgM plasmablasts. Inhibition of BCR-proximal signaling also increased PC numbers and persistence after in vivo engraftment. Leveraging this mechanistic insight, we demonstrated that SYK KO in engineered PCs (ePCs) significantly improved output and in vivo durability of IgM-cetuximab–secreting ePCs. Together, these findings reveal IgM-BCR signaling as a previously unrecognized negative regulator of human IgM PC differentiation and survival and show that inhibition of BCR-proximal pathways can improve IgM-based cellular immunotherapies.
- Open Access
- 8 August 2022
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 219 (9)
IgM antibodies derived from memory B cells are potent cross-variant neutralizers of SARS-CoV-2
Humoral immunity to SARS-CoV-2 can be supplemented with polyclonal sera from convalescent donors or an engineered monoclonal antibody (mAb) product. While pentameric IgM antibodies are responsible for much of convalescent sera’s neutralizing capacity, all available mAbs are based on the monomeric IgG antibody subtype. We now show that IgM mAbs derived from immune memory B cell receptors are potent neutralizers of SARS-CoV-2. IgM mAbs outperformed clonally identical IgG antibodies across a range of affinities and SARS-CoV-2 receptor-binding domain epitopes. Strikingly, efficacy against SARS-CoV-2 viral variants was retained for IgM but not for clonally identical IgG. To investigate the biological role for IgM memory in SARS-CoV-2, we also generated IgM mAbs from antigen-experienced IgM+ memory B cells in convalescent donors, identifying a potent neutralizing antibody. Our results highlight the therapeutic potential of IgM mAbs and inform our understanding of the role for IgM memory against a rapidly mutating pathogen.
- 8 August 2022
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 219 (9)
Open AccessIgM antibodies derived from memory B cells are potent cross-variant neutralizers of SARS-CoV-2
Humoral immunity to SARS-CoV-2 can be supplemented with polyclonal sera from convalescent donors or an engineered monoclonal antibody (mAb) product. While pentameric IgM antibodies are responsible for much of convalescent sera’s neutralizing capacity, all available mAbs are based on the monomeric IgG antibody subtype. We now show that IgM mAbs derived from immune memory B cell receptors are potent neutralizers of SARS-CoV-2. IgM mAbs outperformed clonally identical IgG antibodies across a range of affinities and SARS-CoV-2 receptor-binding domain epitopes. Strikingly, efficacy against SARS-CoV-2 viral variants was retained for IgM but not for clonally identical IgG. To investigate the biological role for IgM memory in SARS-CoV-2, we also generated IgM mAbs from antigen-experienced IgM+ memory B cells in convalescent donors, identifying a potent neutralizing antibody. Our results highlight the therapeutic potential of IgM mAbs and inform our understanding of the role for IgM memory against a rapidly mutating pathogen.
- Open Access
- 4 March 2021
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 218 (4)
Multimeric antibodies from antigen-specific human IgM+ memory B cells restrict Plasmodium parasites
Multimeric immunoglobulin-like molecules arose early in vertebrate evolution, yet the unique contributions of multimeric IgM antibodies to infection control are not well understood. This is partially due to the difficulty of distinguishing low-affinity IgM, secreted rapidly by plasmablasts, from high-affinity antibodies derived from later-arising memory cells. We developed a pipeline to express B cell receptors (BCRs) from Plasmodium falciparum–specific IgM+ and IgG+ human memory B cells (MBCs) as both IgM and IgG molecules. BCRs from both subsets were somatically hypermutated and exhibited comparable monomeric affinity. Crystallization of one IgM+ MBC-derived antibody complexed with antigen defined a linear epitope within a conserved Plasmodium protein. In its physiological multimeric state, this antibody displayed exponentially higher antigen binding than a clonally identical IgG monomer, and more effectively inhibited P. falciparum invasion. Forced multimerization of this IgG significantly improved both antigen binding and parasite restriction, underscoring how avidity can alter antibody function. This work demonstrates the potential of high-avidity IgM in both therapeutics and vaccines.
- 4 March 2021
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 218 (4)
Open AccessMultimeric antibodies from antigen-specific human IgM+ memory B cells restrict Plasmodium parasites
Multimeric immunoglobulin-like molecules arose early in vertebrate evolution, yet the unique contributions of multimeric IgM antibodies to infection control are not well understood. This is partially due to the difficulty of distinguishing low-affinity IgM, secreted rapidly by plasmablasts, from high-affinity antibodies derived from later-arising memory cells. We developed a pipeline to express B cell receptors (BCRs) from Plasmodium falciparum–specific IgM+ and IgG+ human memory B cells (MBCs) as both IgM and IgG molecules. BCRs from both subsets were somatically hypermutated and exhibited comparable monomeric affinity. Crystallization of one IgM+ MBC-derived antibody complexed with antigen defined a linear epitope within a conserved Plasmodium protein. In its physiological multimeric state, this antibody displayed exponentially higher antigen binding than a clonally identical IgG monomer, and more effectively inhibited P. falciparum invasion. Forced multimerization of this IgG significantly improved both antigen binding and parasite restriction, underscoring how avidity can alter antibody function. This work demonstrates the potential of high-avidity IgM in both therapeutics and vaccines.